Advertisement
INGN vs VCYT
Which Stock Would AI Choose? Inogen (INGN) vs. Veracyte (VCYT) Stock Comparison
Key Takeaways
- Different business models: INGN (Inogen) sells respiratory medical devices, while VCYT (Veracyte) sells genomic diagnostic tests.
- Profitability contrast: VCYT is solidly profitable and growing, while INGN remains loss-making on an adjusted basis.
- Scale difference: VCYT's market capitalization is roughly 20 times larger than INGN's, reflecting materially different stages of maturity.
- Momentum split: VCYT posted double-digit testing growth but saw a sharp recent pullback; INGN has trended higher but carries ongoing channel-mix headwinds.
- Balance sheets are strengths for both: Each company holds substantial cash and carries essentially no debt.
Introduction
Investors evaluating small- and mid-cap healthcare names often weigh growth potential against profitability, momentum against valuation. This stock comparison examines INGN and VCYT, two Nasdaq-listed medical technology companies with very different profiles. Inogen, a respiratory device maker, is undergoing a portfolio and channel transition, while Veracyte, a genomic diagnostics leader, is scaling profitable test franchises. For traders focused on relative performance and market positioning, the two names offer a useful contrast: a turnaround story trading near single-digit prices versus an established growth franchise navigating a valuation reset. Understanding the catalysts and risks behind each helps clarify which stock may currently hold the more consistent technical and fundamental edge.
INGN Overview and Recent Performance
INGN, or Inogen, Inc., develops and markets portable oxygen concentrators and broader respiratory products for patients with chronic conditions such as COPD (chronic obstructive pulmonary disease). In recent quarters the company has expanded beyond its original portable oxygen focus into sleep therapy, airway clearance, and digital health, citing a total addressable market of more than $3.4 billion. Recent results showed low-single-digit revenue growth, with international sales growing in the high teens while U.S. direct-to-consumer and rental channels declined amid a structural shift toward portable concentrators. Inogen remains unprofitable on both a GAAP (generally accepted accounting principles) and adjusted basis, though adjusted gross margin has improved modestly. A notable recent development was the announced divestiture of its U.S. oxygen rental business for up to $25 million, accompanied by an increase in its share repurchase authorization. The stock has traded with notable volatility but has trended higher in recent weeks, supported by analyst Buy ratings and price targets well above its single-digit share price.
VCYT Overview and Recent Performance
VCYT, or Veracyte, Inc., provides advanced genomic diagnostic tests, with flagship franchises in Decipher Prostate and Afirma (thyroid cancer), alongside newer launches such as Prosigna for breast cancer and TrueMRD for minimal residual disease (the detection of residual cancer after treatment) monitoring. The company has delivered consistent double-digit testing-volume and revenue growth, recently reporting revenue growth in the mid-teens and strong growth in adjusted earnings, which led management to raise full-year guidance. Veracyte is profitable, generates meaningful free cash flow, and holds roughly $485 million in cash with no current debt. Despite this operating strength, the stock experienced a pronounced sell-off of more than 25% over a one-month stretch, reflecting reimbursement uncertainty around newer tests and a premium valuation. New clinical data on Decipher presented at a recent oncology meeting and continued test-volume growth have helped stabilize sentiment, though the shares remain below prior highs.
Trending AI Robots
For traders seeking a more systematic approach to names like these, Tickeron's Trending AI Robots page offers a curated view of its AI-powered trading bots. Tickeron hosts hundreds of AI Trading Bots that trade thousands of different tickers, yet only the best-performing and most suitable for current market conditions are featured in this section. These bots vary widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they trade, so the curated list is designed to surface those currently aligned with prevailing market dynamics. Exploring the page can help traders identify automated strategies that match their own objectives and risk tolerance.
Head-to-Head Comparison
The clearest divergence between INGN and VCYT is the stage of business maturity. Veracyte operates a diversified, revenue-generating test portfolio with a track record of profitable growth, while Inogen is still transitioning its product mix and working toward sustained profitability. On growth drivers, VCYT leans on test-volume gains, guideline support, and new oncology launches; INGN relies on international expansion and new product categories to offset U.S. channel declines. Risk profiles differ as well: VCYT faces reimbursement and commercialization execution risk at a premium valuation, whereas INGN faces channel-mix pressure and persistent operating losses. Sector exposure is broadly similar—both sit in healthcare and medical technology—but Veracyte's higher beta and recent volatility contrast with Inogen's smaller, lower-liquidity float. From a sentiment standpoint, Veracyte has favorable earnings-estimate revisions despite the recent pullback, while Inogen benefits from analyst upside targets but lacks the same profitability support.
Tickeron AI Verdict
Based on observable factors such as trend consistency, stability, catalysts, and relative positioning, Tickeron's AI would likely favor VCYT at present. Veracyte combines a profitable operating base, double-digit growth, a debt-free balance sheet, and positive earnings-estimate momentum—attributes that tend to support more durable technical trends. Inogen offers a genuine turnaround catalyst and meaningful analyst upside, but its unprofitable status and ongoing channel transition introduce greater fundamental uncertainty. The verdict is probabilistic rather than definitive: VCYT's steadier growth and improving estimates give it the edge on trend quality, while INGN's recovery story remains viable but more dependent on execution. Traders should weigh this framework against their own time horizon and risk preferences.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is INGN is a StrongBuy and VCYT is a StrongBuy.
INGN in upward trend: price rose above 50-day moving average on October 01, 2026
INGN moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 24, 2026. You may want to consider a long position or call options on INGN as a result. In 62 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The 10-day moving average for INGN crossed bullishly above the 50-day moving average on October 08, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.
Following a +6.45% 3-day Advance, the price is estimated to grow further. Considering data from situations where INGN advanced for three days, in 188 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
The Aroon Indicator entered an Uptrend today. In 115 of 169 cases where INGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 68%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
INGN broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. INGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.078) is normal, around the industry mean (2.914). P/E Ratio (-7.802) is within average values for comparable stocks, (1.904). Projected Growth (PEG Ratio) (1.290) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.393) is also within normal values, averaging (40.124).
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. INGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
VCYT in upward trend: 10-day moving average crossed above 50-day moving average on October 02, 2026
The 10-day moving average for VCYT crossed bullishly above the 50-day moving average on October 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 12 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VCYT's RSI Oscillator exited the oversold zone, 17 of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on VCYT as a result. In 87 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for VCYT just turned positive on October 21, 2026. Looking at past instances where VCYT's MACD turned positive, the stock continued to rise in 41 of 51 cases over the following month. The odds of a continued upward trend are 80%.
VCYT moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.53% 3-day Advance, the price is estimated to grow further. Considering data from situations where VCYT advanced for three days, in 202 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VCYT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
VCYT broke above its upper Bollinger Band on October 23, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for VCYT entered a downward trend on September 17, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating fairly steady price growth. VCYT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.775) is normal, around the industry mean (66.137). P/E Ratio (33.285) is within average values for comparable stocks, (2.464). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (5.583) is also within normal values, averaging (9.775).
The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 94 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 98 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VCYT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
INGN | VCYT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 27 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 60 Fair valued | 70 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 98 | |
SMR RATING 1..100 | 94 | 75 | |
PRICE GROWTH RATING 1..100 | 39 | 44 | |
P/E GROWTH RATING 1..100 | 57 | 94 | |
SEASONALITY SCORE 1..100 | 50 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
INGN's Valuation (60) in the Medical Specialties industry is in the same range as VCYT (70) in the Biotechnology industry. This means that INGN’s stock grew similarly to VCYT’s over the last 12 months.
VCYT's Profit vs Risk Rating (98) in the Biotechnology industry is in the same range as INGN (100) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to INGN’s over the last 12 months.
VCYT's SMR Rating (75) in the Biotechnology industry is in the same range as INGN (94) in the Medical Specialties industry. This means that VCYT’s stock grew similarly to INGN’s over the last 12 months.
INGN's Price Growth Rating (39) in the Medical Specialties industry is in the same range as VCYT (44) in the Biotechnology industry. This means that INGN’s stock grew similarly to VCYT’s over the last 12 months.
INGN's P/E Growth Rating (57) in the Medical Specialties industry is somewhat better than the same rating for VCYT (94) in the Biotechnology industry. This means that INGN’s stock grew somewhat faster than VCYT’s over the last 12 months.
| INGN | VCYT | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 5 days ago 85% |
| Stochastic ODDS (%) | 1 day ago 81% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 70% | 1 day ago 83% |
| MACD ODDS (%) | N/A | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 74% | 1 day ago 75% |
| TrendMonth ODDS (%) | 1 day ago 73% | 1 day ago 81% |
| Advances ODDS (%) | 1 day ago 71% | 3 days ago 73% |
| Declines ODDS (%) | 10 days ago 82% | 11 days ago 79% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 68% | 5 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
INGN’s FA Score shows that 0 FA rating(s) are green while VCYT’s FA Score has 0 green FA rating(s).
- INGN’s FA Score: 0 green, 5 red.
- VCYT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
INGN’s TA Score shows that 5 TA indicator(s) are bullish while VCYT’s TA Score has 6 bullish TA indicator(s).
- INGN’s TA Score: 5 bullish, 4 bearish.
- VCYT’s TA Score: 6 bullish, 4 bearish.
Price Growth
INGN (@Medical/Nursing Services) experienced а +13.60% price change this week, while VCYT (@Medical Specialties) price change was +11.15% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.51%. For the same industry, the average monthly price growth was -9.72%, and the average quarterly price growth was -10.64%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.55%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
Reported Earning Dates
INGN is expected to report earnings on Nov 05, 2026.
VCYT is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical/Nursing Services (-0.51% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
INGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, INGN has been loosely correlated with VCYT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if INGN jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To INGN | 1D Price Change % | ||
|---|---|---|---|---|
| INGN | 100% | +0.85% | ||
| VCYT - INGN | 46% Loosely correlated | +4.11% | ||
| STRRP - INGN | 44% Loosely correlated | -1.64% | ||
| OSUR - INGN | 39% Loosely correlated | +8.68% | ||
| IRTC - INGN | 39% Loosely correlated | +1.36% | ||
| ENOV - INGN | 37% Loosely correlated | -2.36% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| JHDG | 27.85 | 0.07 | +0.25% |
| John Hancock Hedged Equity ETF (JHDG) | |||
| DGJA | 32.31 | N/A | N/A |
| FT Vest U.S. Equity Buffer & Digital Return ETF - January (DGJA) | |||
| GDEC | 40.86 | -0.09 | -0.21% |
| FT Vest U.S. Equity Moderate Buffer ETF - December (GDEC) | |||
| PFFA | 18.78 | -0.15 | -0.79% |
| Virtus InfraCap U.S. Preferred Stock ETF (PFFA) | |||
| NOVZ | 47.33 | -0.43 | -0.90% |
| TrueShares Structured Outcome (November) ETF (NOVZ) | |||